Molecular Diagnostics News and Research

RSS

New collaborative study aims to identify mutations to improve clinical management of breast cancer

Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen's University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.

18 Aug 2016

AMP releases new report that addresses challenges in defining clinical utility of molecular diagnostics

The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostic professionals, today announced a new report that addresses the challenges in defining the clinical utility of molecular diagnostics for inherited diseases and cancer.

17 Aug 2016

NIH researchers design new set of assays for initial screening of patients with Fragile X syndrome

Fragile X syndrome, the most common heritable cause of intellectual disability and a frequent cause of autism, is characterized by abnormalities of the FMR1 gene that are difficult to analyze.

12 Aug 2016

Sophia Genetics reveals world’s most advanced collective artificial intelligence platform

Sophia Genetics, the global leader in Data-Driven Medicine, today unveiled SOPHiA, the world’s most advanced collective artificial intelligence (AI) for Data-Driven Medicine.

29 Jul 2016

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades.

14 Jul 2016

Insilico Medicine collaborates with Asia Genomics to develop advanced personalized longevity suite

Insilico Medicine Inc, a big data analytics company located at the Emerging Technology Centers at the Johns Hopkins University at Eastern, announced an agreement with Asia Genomics, a Singapore-based rapidly growing molecular diagnostics company specializing in clinical genomics & genetic testing operating in major Asian countries including Vietnam, Malaysia and China.

22 Jun 2016

Molecular diagnostics of the future: an interview with Elaine Warburton, OBE

Firstly, a sample must be transported from the clinic to the laboratory. Simple tests may be undertaken in a small lab within the hospital or clinic, whilst complex testing such as drug susceptibility testing is often done in a large centralized laboratory many miles from the clinic

20 Jun 2016

QIAGEN announces launch of QIAsure Methylation Test to detect cervical cancer risk

QIAGEN N.V. today announced the launch of the QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patients' risk of developing cervical cancer.

From QIAGEN Manchester Limited 15 Jun 2016

New method helps speed up bacterial identification

Pinpointing the type of bacteria that are at the root of an infection in clinical samples removed from living tissues, such as blood, urine or joint fluids, to quickly identify the best anti-microbial therapy still poses a formidable challenge.

10 Jun 2016

New technology can detect KRAS gene mutations, facilitate targeted therapies for lung and colorectal cancers

A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.

8 Jun 2016

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer.

20 May 2016

Epigenomics receives FDA approval for Epi proColon®

Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer screening test.

14 Apr 2016

Advanced assay offers better sensitivity for detecting a prion disease affecting elk

Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a family of rare progressive, neurodegenerative illnesses that affect both humans and animals. TSE surveillance is important for public health and food safety because TSEs have the potential of crossing from animals to humans, as seen with the spread of mad cow disease, or bovine spongiform encephalopathy (BSE). A study in The Journal of Molecular Diagnostics describes an advanced assay that offers better sensitivity than currently available tests for detecting a prion disease affecting elk.

11 Apr 2016

Clinical study shows association between Corus CAD blood test scores and cardiovascular event rates

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial in nondiabetic patients receiving the Corus CAD blood test.

7 Apr 2016

Myriad myRisk Hereditary Cancer test identifies 70% more deleterious mutations than BRCA1/2 testing alone

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency of germline mutations in 25 cancer susceptibility genes among patients with breast cancer.

31 Mar 2016

New device can deliver diagnosis to patient in 30 minutes

When a person contracts a disease, it takes time to diagnose the symptoms. Cell culturing, immunoassay and a nucleic-acid based diagnostic cycle all take several days, if not a week to determine the results. Not only do sick patients suffer during this time period, the wait can also lead to unnecessary disease spreading and perhaps avoidable antibiotic use.

30 Mar 2016

AMP disappointed as FDA takes enforcement action against physicians for Zika virus test

The Association for Molecular Pathology, the premier global, professional society serving molecular diagnostics professionals, is very concerned and disappointed to see the FDA taking enforcement action against the physicians at Texas Children's Hospital and Houston Methodist Hospital for their laboratory developed procedure (LDP) for Zika virus, which was designed to identify virus-specific RNA sequences in a large metropolitan area.

16 Mar 2016

Texas Children's Hospital, Houston Methodist Hospital jointly release country's first rapid test for Zika virus

Collaboration between two Texas Medical Center institutions has resulted in today's release of the country's first hospital-based rapid tests for the Zika virus.

23 Feb 2016

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued.

8 Feb 2016

FedMed gains access to Trovagene's Precision Cancer Monitoring tests and service

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc. establishing health benefit access to Trovagene's full line of Precision Cancer Monitoring (PCM) tests and services.

1 Feb 2016